Dan Friedell adapted this story for Learning English based on a story by The Associated Press
The injectable works systemically to achieve broader goals such as hair growth, wound healing, and whole-body regeneration
TRIUMPH-3 (NCT05882045) will investigate change in bodyweight in people with overweight/obesity and cardiovascular disease, and TRIUMPH-4 (NCT05931367) will assess change in WOMAC score and bodyweight in individuals with overweight/obesity and knee OA
Retatrutide is therefore not available as a licensed medicine in the UK, and any use outside of approved clinical trials would be unlicensed and potentially unsafe
Increasing the dose without consulting your doctor can reduce GLP-1 effectiveness and increase side effects, such as severe nausea or vomiting, diarrhea or constipation, abdominal pain, or extreme loss of appetite 7